证券代码：688410 证券简称：山外山 公告编号：2025-046 重庆山外山血液净化技术股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有股份的基本情况 本次减持计划实施前，重庆山外山血液净化技术股份有限公司（以下简称 "公司"）股东湖南湘江力远投资管理有限公司－湖南湘江大健康创业投资合伙 企业（有限合伙）（以下简称"大健康"）持有公司股份 35,521,600 股，约占公 司总股本的比例 11.06%；湖南湘江力远投资管理有限公司－湖南湘江力远健鲲 创业投资合伙企业（有限合伙）（以下简称"力远健鲲"）持有公司股份 3,886,616 股，约占公司总股本的比例 1.21%；大健康和力远健鲲在公司上市前 已签署《一致行动协议》，系一致行动人，合计持有公司股份 39,408,216 股，占 公司总股本的比例 12.26%。上述股份来源于公司首次公开发行前股份及资本公 积转增股本取得，且已于 2023 年 12 月 26 日起上市流通。 减持计划的实施结果 ...

Core Insights - Pension funds have emerged as significant shareholders in 11 stocks listed on the Sci-Tech Innovation Board, with a total holding of 50.67 million shares valued at 2.647 billion yuan at the end of Q2 [1][2] Group 1: Pension Fund Holdings - Pension funds have newly entered 3 stocks, increased holdings in 2 stocks, and reduced holdings in 4 stocks, while 2 stocks remained unchanged in their holdings [1] - The stock with the highest holding ratio by pension funds is Haitai New Light, accounting for 4.20% of the circulating shares, followed by Rongzhi Rixin and Huafeng Technology at 4.04% and 2.67%, respectively [1] - The top holdings by quantity include Transsion Holdings with 17.72 million shares, Shengyi Electronics with 5.33 million shares, and Yubang Power with 5.19 million shares [1] Group 2: Industry Focus - The stocks held by pension funds are primarily concentrated in the electronics, pharmaceutical, and national defense industries, with 3, 2, and 2 stocks respectively [1] - Eight stocks have been continuously held by pension funds for more than two reporting periods, with Yubang Power and Kaili New Materials being held for 12 reporting periods [1] Group 3: Performance Metrics - Among the stocks held by pension funds, 7 reported year-on-year net profit growth in the first half of the year, with Rongzhi Rixin showing the highest growth of 2063.42% [2] - The average increase of the Sci-Tech Innovation Board stocks held by pension funds since July is 17.32%, with Huafeng Technology leading with a cumulative increase of 40.03% [2] - The stock with the largest decline is Guoke Military Industry, which has decreased by 8.89% [2]

Core Viewpoint - The company reported strong financial performance in the first half of 2025, with significant growth in revenue and net profit, driven by its leading position in the domestic blood purification equipment market and increased sales of self-produced consumables [1][2]. Group 1: Financial Performance - The company achieved a revenue of 357 million yuan in the first half of 2025, representing a year-on-year growth of 28.72% [1] - The net profit attributable to shareholders was 55.04 million yuan, up 20.28% year-on-year, with basic earnings per share of 0.17 yuan, also reflecting a growth of 20.29% [1] - In Q2 alone, revenue reached 168 million yuan, marking a 45.51% increase year-on-year, while net profit for the quarter was 18.03 million yuan, up 56.47% [1] Group 2: Market Position and Growth Drivers - The company is recognized as a leading player in the domestic blood purification equipment market, with a market share increase in CRRT devices to 20.42% in the first half of 2025, up from 18.18% in the same period last year [1] - The market share for blood dialysis machines also rose to 15.29%, compared to 10.35% year-on-year, maintaining the top position among domestic brands [1] - The revenue from blood purification consumables reached 85.34 million yuan, showing a year-on-year growth of 46.17%, with self-produced consumables growing by 91.90% [2] Group 3: Strategic Initiatives - The company has established an independent sales team to enhance the synergy between equipment and consumables, focusing on penetrating public hospitals and strengthening partnerships with medical groups and dialysis centers [2] - The international market strategy is being deepened, with significant revenue growth in overseas markets, particularly in North America and Africa, where sales increased by 41.30% to 86.82 million yuan [2] Group 4: Profit Forecast and Valuation - The company is expected to see net profits of 151 million yuan, 191 million yuan, and 238 million yuan for the years 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 34.3, 27.2, and 21.8 times [3]

证券代码：688410 证券简称：山外山 公告编号：2025-045 重庆山外山血液净化技术股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告 股东湖南湘江力远投资管理有限公司-湖南湘江大健康创业投资合伙企业（有限 合伙）（以下简称"大健康"或"信息披露义务人"）、湖南湘江力远投资管理有限公 司-湖南湘江力远健鲲创业投资合伙企业（有限合伙）（以下简称"力远健鲲"）保 证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人的基本信息 1.身份类别 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | 湖南湘江力远投资 | □ | 控股股东/实控人 | | | 管理有限公司-湖 | □ | 控股股东/实控人的一致行动 | 91430100394035926G ☑ | | 南湘江大健康创业 | 人 | | □不适用 | | 投资合伙企业（有 | ☑ | 其他直接持股股东 | | 重要内容提示： 权益变动方向 比例增 ...

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the employee stock ownership plan and daily related transactions [1][4][8] Group 1: Meeting Details - The meeting is scheduled for September 4, 2025, at 14:30, located at the company's office in Chongqing [4] - The meeting will be conducted both in-person and online, with specific voting times outlined for shareholders [4] - The agenda includes the introduction of attendees, discussion of proposals, and voting on the resolutions [4][8] Group 2: Proposal on Employee Stock Ownership Plan - The company proposes to repurchase and cancel 1,715,024 shares from the 2024 employee stock ownership plan due to unmet performance conditions [8][10] - The repurchase price is set at 8.23 yuan per share, adjusted from the original price of 12.27 yuan per share [10][11] - The funding for the repurchase will come from the company's own funds, and the cancellation will not affect the control of the company [11][12] Group 3: Daily Related Transactions - The company plans to increase the expected amount for daily related transactions in 2025, with a total expected amount of 5,990 million yuan [6][8] - The increase is primarily due to the need to meet procurement demands from related parties [6][7] - The transactions will adhere to fair market pricing principles and will not harm the interests of shareholders [7][8]

Core Viewpoint - The report outlines the ongoing supervisory work conducted by Western Securities for Chongqing Mountain Outside Blood Purification Technology Co., Ltd. (Mountain Outside), emphasizing compliance with regulations and the company's operational status post-IPO [1][2]. Group 1: Supervisory Work - The sponsor has established and effectively implemented a continuous supervision work system, creating specific work plans for ongoing oversight [1]. - A continuous supervision agreement was signed between the sponsor and Mountain Outside, clarifying the rights and obligations of both parties during the supervision period [1]. - The sponsor conducts regular communication, visits, and on-site inspections to understand Mountain Outside's business situation [1][2]. Group 2: Financial Performance - For the first half of 2025, the company reported operating income of CNY 357.25 million, a year-on-year increase of 28.72% [14]. - The total profit reached CNY 60.14 million, reflecting a growth of 34.55% compared to the previous year [14]. - The net profit attributable to shareholders was CNY 55.04 million, marking a 20.28% increase year-on-year [14]. Group 3: Research and Development - The company increased its R&D investment by 37.12% in the first half of 2025, totaling CNY 36.51 million, which represents 10.22% of its operating income [24][25]. - The R&D team expanded to 236 personnel, a growth of 38.01% compared to the previous year [24]. - The company has obtained various patents and certifications, including 62 invention patents and CE certifications for several products, enhancing its competitive edge in the market [19][25]. Group 4: Market Position and Competition - Mountain Outside is positioned as a leading domestic manufacturer of blood purification equipment, benefiting from technological advantages and brand recognition [14][16]. - The company faces competition from established international brands, necessitating continuous innovation and product upgrades to maintain market share [11][12]. - The domestic market for blood purification devices is characterized by intense competition, with imported brands holding significant market shares [11][12]. Group 5: Risk Factors - The company is exposed to various risks, including core competitiveness risks related to technology and talent retention, operational risks associated with regulatory compliance, and financial risks linked to accounts receivable [4][9][10]. - The potential impact of changes in national healthcare policies and market dynamics poses additional challenges to the company's growth and profitability [12][13]. - The company is actively monitoring macroeconomic conditions and trade relations to mitigate risks associated with currency fluctuations and global trade disputes [13].

关于重庆山外山血液净化技术股份有限公司 2025 年半年度持续督导跟踪报告 西部证券股份有限公司 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为重庆 山外山血液净化技术股份有限公司（以下简称"山外山"、"公司"）持续督导工 作的保荐人，负责山外山上市后的持续督导工作，并出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并针 | 保荐人己建立健全并有效执行了 | | 1 | | 持续督导制度，并制定了相应的 | | | 对具体的持续督导工作制定相应的工作计划 | 工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开 | 保荐人己与山外山签订《保荐协 | | | 始前，与上市公司签署持续督导协议，明确双 | 议》，该协议明确了双方在持续督 | | | 方在持续督导期间的权利义务，并报上海证券 | 导期间的权利和义务，并报上海 | | ...

重庆山外山血液净化技术股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 9 月 4 日 重庆山外山血液净化技术股份有限公司 2025 年第二次临时股东大会会议资料 重庆山外山血液净化技术股份有限公司 2025 年第二次临时股东大会 会议资料 证券代码：688410 证券简称：山外山 目录 重庆山外山血液净化技术股份有限公司 2025 年第二次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《中华人民共和国公司法》、中国证监会《上市公司股东会规则》和公司《股 东大会议事规则》等有关规定，特制定本会议须知： 一、公司负责本次股东大会的议程安排和会务工作，为确认出席大会的股东 或其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行 必要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照/注册证书复印件 （加盖公章）、授权委托书等，上述登记材料均需提供复印件一份，个人登记材 料复印件须个人签字，法定代表人证明文件复印件须加盖公司公章 ...

Core Insights - The recent disclosure of semi-annual reports by A-share listed companies reveals significant movements among institutional investors, particularly pension funds [1] Group 1: Institutional Investment Trends - In the second quarter, pension funds entered the top ten circulating shareholder lists of over 20 stocks [1] - The total market value of stocks newly held by pension funds, with a market value exceeding 100 million yuan, includes 11 companies: Hongfa Technology, Satellite Chemical, Shengyi Electronics, Yuyue Medical, Jereh Group, Angel Yeast, Taineng Technology, Huace Testing, Hisense Home Appliances, Gongda Electronics, and Cambridge Technology [1] - Additionally, pension funds also entered the top ten circulating shareholder lists of companies such as Weichai Heavy Machinery, Huafeng Aluminum, Luxi Chemical, Jingneng Electric Power, Nova Star Cloud, Fuda Co., Tianqin Equipment, Shanhaishan, Gaoxingxing, Jiuzhitang, Doli Technology, Zhongce Rubber, Weifeng Electronics, and Baolijia [1]

山外山8月22日报收16.27元，较前一交易日下跌1.63%。当日成交量为105590手，成交金额达1.71亿 元。 风险提示：股市有风险，投资需谨慎。 来源:金融界 资金流向方面，山外山当日主力资金净流出1038.47万元，近五日累计净流出4867.53万元。 该公司属于医疗器械行业，专注于血液净化设备及耗材的研发生产。公开资料显示，二季度末基本养老 保险基金一六零二二组合新进成为山外山第十大流通股东，持有200.45万股，占流通股比例0.85%。 ...